Dongxing Zha

Dongxing Zha, CTO of TCR Discovery & Engineering and CEO of Keyway TCR Discovery at Alloy Therapeutics, is a biotechnology ecosystem company empowering the global scientific community to make better medicine together. Dongxing has over 20 years of experience in the biotechnology industry.

Dongxing started their career as a Research Fellow and Group Leader at Merck, where they worked for 8 years. Dongxing then moved to GlycoFi as a Senior Research Scientist, where they worked for 3 years. After that, they became a Postdoctoral Fellow at Max-Planck-Institut für Kohlenforschung, where they worked for 3 years. Dongxing then worked as a Research Scientist at Novo Nordisk for 1 year before joining Alloy Therapeutics.

At Alloy Therapeutics, Dongxing is responsible for the company's technology and product development. Dongxing has also founded Keyway TCR Discovery, which is a subsidiary of Alloy Therapeutics.

Dongxing Zha has a PhD in Microbiology from Huazhong Agricultural University and a BS in Biology from Anhui Normal University.